Skip to main content
Erschienen in: Cellular Oncology 2/2020

17.12.2019 | Review

Esophageal carcinoma: Towards targeted therapies

verfasst von: Ali Fatehi Hassanabad, Rania Chehade, Daniel Breadner, Jacques Raphael

Erschienen in: Cellular Oncology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Patients with esophageal cancer are confronted with high mortality rates. Whether it is esophageal squamous cell carcinoma (ESCC) or esophageal adenocarcinoma (EAC), patients usually present at advanced stages, with treatment options traditionally involving chemotherapy in metastatic settings. With the comprehensive genomic characterization of esophageal cancers, targeted therapies are gaining interest and agents such as ramucirumab, trastuzumab and pembrolizumab are already being used for the treatment of EAC.

Conclusions

Pembrolizumab has recently been FDA-approved for PD-L1 positive, locally advanced or metastatic ESCC. Despite comprehensive molecular characterization, however, available targed therapies for ESCC are still lagging behind. Herein, we discuss current trends towards more targeted therapies in esophageal cancers, taking into consideration unique features of ESCCs and EACs. Patients progressing on standard therapies should be subjected to genomic profiling and considered for clinical trials aimed at testing targeted therapies. Future targeted therapies may include CDK4/6 inhibitors, PARP inhibitors and inhibitors targeting the NRF2 and Wnt signaling pathways. Ultimately, optimized biomarker assays and next generation sequencing platforms may allow for the identification of subcategories of ESCC and EAC patients that will benefit from selective targeted therapies and/or combinations thereof.
Literatur
1.
Zurück zum Zitat J. Lagergren, E. Smyth, D. Cunningham, P. Lagergren, Oesophageal cancer. Lancet 390, 2383–2396 (2017)CrossRefPubMed J. Lagergren, E. Smyth, D. Cunningham, P. Lagergren, Oesophageal cancer. Lancet 390, 2383–2396 (2017)CrossRefPubMed
2.
Zurück zum Zitat Cancer Genome Atlas Research Network; Analysis Working Group: Asan University; BC Cancer Agency; Brigham and Women’s Hospital; Broad Institute; Brown University; Case Western Reserve University; Dana-Farber Cancer Institute; Duke University; Greater Poland Cancer Centre; Harvard Medical School; Institute for Systems Biology; KU Leuven; Mayo Clinic; Memorial Sloan Kettering Cancer Center; National Cancer Institute; Nationwide Children’s Hospital; Stanford University; University of Alabama; University of Michigan; University of North Carolina; University of Pittsburgh; University of Rochester; University of Southern California; University of Texas MD Anderson Cancer Center; University of Washington; Van Andel Research Institute; Vanderbilt University; Washington University; Genome Sequencing Center: Broad Institute; Washington University in St. Louis; Genome Characterization Centers: BC Cancer Agency; Broad Institute; Harvard Medical School; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University; University of North Carolina; University of Southern California Epigenome Center; University of Texas MD Anderson Cancer Center; Van Andel Research Institute; Genome Data Analysis Centers: Broad Institute; Brown University:; Harvard Medical School; Institute for Systems Biology; Memorial Sloan Kettering Cancer Center; University of California Santa Cruz; University of Texas MD Anderson Cancer Center; Biospecimen Core Resource: International Genomics Consortium; Research Institute at Nationwide Children’s Hospital; Tissue Source Sites: Analytic Biologic Services; Asan Medical Center; Asterand Bioscience; Barretos Cancer Hospital; BioreclamationIVT; Botkin Municipal Clinic; Chonnam National University Medical School; Christiana Care Health System; Cureline; Duke University; Emory University; Erasmus University; Indiana University School of Medicine; Institute of Oncology of Moldova; International Genomics Consortium; Invidumed; Israelitisches Krankenhaus Hamburg; Keimyung University School of Medicine; Memorial Sloan Kettering Cancer Center; National Cancer Center Goyang; Ontario Tumour Bank; Peter MacCallum Cancer Centre; Pusan National University Medical School; Ribeirão Preto Medical School; St. Joseph’s Hospital &Medical Center; St. Petersburg Academic University; Tayside Tissue Bank; University of Dundee; University of Kansas Medical Center; University of Michigan; University of North Carolina at Chapel Hill; University of Pittsburgh School of Medicine; University of Texas MD Anderson Cancer Center; Disease Working Group: Duke University; Memorial Sloan Kettering Cancer Center; National Cancer Institute; University of Texas MD Anderson Cancer Center; Yonsei University College of Medicine; Data Coordination Center: CSRA Inc.; Project Team: National Institutes of Health, Integrated genomic characterization of oesophageal carcinoma. Nature 541, 169–175 (2017)CrossRef Cancer Genome Atlas Research Network; Analysis Working Group: Asan University; BC Cancer Agency; Brigham and Women’s Hospital; Broad Institute; Brown University; Case Western Reserve University; Dana-Farber Cancer Institute; Duke University; Greater Poland Cancer Centre; Harvard Medical School; Institute for Systems Biology; KU Leuven; Mayo Clinic; Memorial Sloan Kettering Cancer Center; National Cancer Institute; Nationwide Children’s Hospital; Stanford University; University of Alabama; University of Michigan; University of North Carolina; University of Pittsburgh; University of Rochester; University of Southern California; University of Texas MD Anderson Cancer Center; University of Washington; Van Andel Research Institute; Vanderbilt University; Washington University; Genome Sequencing Center: Broad Institute; Washington University in St. Louis; Genome Characterization Centers: BC Cancer Agency; Broad Institute; Harvard Medical School; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University; University of North Carolina; University of Southern California Epigenome Center; University of Texas MD Anderson Cancer Center; Van Andel Research Institute; Genome Data Analysis Centers: Broad Institute; Brown University:; Harvard Medical School; Institute for Systems Biology; Memorial Sloan Kettering Cancer Center; University of California Santa Cruz; University of Texas MD Anderson Cancer Center; Biospecimen Core Resource: International Genomics Consortium; Research Institute at Nationwide Children’s Hospital; Tissue Source Sites: Analytic Biologic Services; Asan Medical Center; Asterand Bioscience; Barretos Cancer Hospital; BioreclamationIVT; Botkin Municipal Clinic; Chonnam National University Medical School; Christiana Care Health System; Cureline; Duke University; Emory University; Erasmus University; Indiana University School of Medicine; Institute of Oncology of Moldova; International Genomics Consortium; Invidumed; Israelitisches Krankenhaus Hamburg; Keimyung University School of Medicine; Memorial Sloan Kettering Cancer Center; National Cancer Center Goyang; Ontario Tumour Bank; Peter MacCallum Cancer Centre; Pusan National University Medical School; Ribeirão Preto Medical School; St. Joseph’s Hospital &Medical Center; St. Petersburg Academic University; Tayside Tissue Bank; University of Dundee; University of Kansas Medical Center; University of Michigan; University of North Carolina at Chapel Hill; University of Pittsburgh School of Medicine; University of Texas MD Anderson Cancer Center; Disease Working Group: Duke University; Memorial Sloan Kettering Cancer Center; National Cancer Institute; University of Texas MD Anderson Cancer Center; Yonsei University College of Medicine; Data Coordination Center: CSRA Inc.; Project Team: National Institutes of Health, Integrated genomic characterization of oesophageal carcinoma. Nature 541, 169–175 (2017)CrossRef
3.
Zurück zum Zitat Y.B. Gao, Z.L. Chen, J.G. Li, X.D. Hu, X.J. Shi, Z.M. Sun, F. Zhang, Z.R. Zhao, Z.T. Li, Z.Y. Liu, Y.D. Zhao, J. Sun, C.C. Zhou, R. Yao, S.Y. Wang, P. Wang, N. Sun, B.H. Zhang, J.S. Dong, Y. Yu, M. Luo, X.L. Feng, S.S. Shi, F. Zhou, F.W. Tan, B. Qiu, N. Li, K. Shao, L.J. Zhang, Q. Xue, S.G. Gao, J. He, Genetic landscape of esophageal squamous cell carcinoma. Nat Genet 46, 1097–1102 (2014) Y.B. Gao, Z.L. Chen, J.G. Li, X.D. Hu, X.J. Shi, Z.M. Sun, F. Zhang, Z.R. Zhao, Z.T. Li, Z.Y. Liu, Y.D. Zhao, J. Sun, C.C. Zhou, R. Yao, S.Y. Wang, P. Wang, N. Sun, B.H. Zhang, J.S. Dong, Y. Yu, M. Luo, X.L. Feng, S.S. Shi, F. Zhou, F.W. Tan, B. Qiu, N. Li, K. Shao, L.J. Zhang, Q. Xue, S.G. Gao, J. He, Genetic landscape of esophageal squamous cell carcinoma. Nat Genet 46, 1097–1102 (2014)
4.
Zurück zum Zitat D.C. Lin, J.J. Hao, Y. Nagata, L. Xu, L. Shang, X. Meng, Y. Sato, Y. Okuno, A.M. Varela, L.W. Ding, M. Garg, L.Z. Liu, H. Yang, D. Yin, Z.Z. Shi, Y.Y. Jiang, W.Y. Gu, T. Gong, Y. Zhang, X. Xu, O. Kalid, S. Shacham, S. Ogawa, M.R. Wang, H.P. Koeffler, Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet 46, 467–473 (2014)CrossRefPubMedPubMedCentral D.C. Lin, J.J. Hao, Y. Nagata, L. Xu, L. Shang, X. Meng, Y. Sato, Y. Okuno, A.M. Varela, L.W. Ding, M. Garg, L.Z. Liu, H. Yang, D. Yin, Z.Z. Shi, Y.Y. Jiang, W.Y. Gu, T. Gong, Y. Zhang, X. Xu, O. Kalid, S. Shacham, S. Ogawa, M.R. Wang, H.P. Koeffler, Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet 46, 467–473 (2014)CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat C.C. Abnet, M. Arnold, W.Q. Wei, Epidemiology of esophageal squamous cell carcinoma. Gastroenterology 154, 360–373 (2018)CrossRefPubMed C.C. Abnet, M. Arnold, W.Q. Wei, Epidemiology of esophageal squamous cell carcinoma. Gastroenterology 154, 360–373 (2018)CrossRefPubMed
6.
Zurück zum Zitat E.C. Smyth, J. Lagergren, R.C. Fitzgerald, F. Lordick, M.A. Shah, P. Lagergren, D. Cunningham, Oesophageal cancer. Nat Rev Dis Primers 3, 17048 (2017)CrossRefPubMedPubMedCentral E.C. Smyth, J. Lagergren, R.C. Fitzgerald, F. Lordick, M.A. Shah, P. Lagergren, D. Cunningham, Oesophageal cancer. Nat Rev Dis Primers 3, 17048 (2017)CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat J. Rüdiger Siewert, M. Feith, M. Werner, H.J. Stein, Adenocarcinoma of the esophagogastric junction: Results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 232, 353–361 (2000) J. Rüdiger Siewert, M. Feith, M. Werner, H.J. Stein, Adenocarcinoma of the esophagogastric junction: Results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 232, 353–361 (2000)
8.
Zurück zum Zitat F.L. Huang, S.J. Yu, Esophageal cancer: Risk factors, genetic association, and treatment. Asian J Surg 41, 210–215 (2018)CrossRefPubMed F.L. Huang, S.J. Yu, Esophageal cancer: Risk factors, genetic association, and treatment. Asian J Surg 41, 210–215 (2018)CrossRefPubMed
9.
Zurück zum Zitat M.Q. Lin, Y.P. Li, S.G. Wu, J.Y. Sun, H.X. Lin, S.Y. Zhang, Z.Y. He, Differences in esophageal cancer characteristics and survival between Chinese and Caucasian patients in the SEER database. Onco Targets Ther 9, 6435–6444 (2016)CrossRefPubMedPubMedCentral M.Q. Lin, Y.P. Li, S.G. Wu, J.Y. Sun, H.X. Lin, S.Y. Zhang, Z.Y. He, Differences in esophageal cancer characteristics and survival between Chinese and Caucasian patients in the SEER database. Onco Targets Ther 9, 6435–6444 (2016)CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Y. Kitagawa, T. Uno, T. Oyama, K. Kato, H. Kato, H. Kawakubo, O. Kawamura, M. Kusano, H. Kuwano, H. Takeuchi, Y. Toh, Y. Doki, Y. Naomoto, K. Nemoto, E. Booka, H. Matsubara, T. Miyazaki, M. Muto, A. Yanagisawa, M. Yoshida, Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: Part 2. Esophagus 16, 25–43 (2019)CrossRefPubMed Y. Kitagawa, T. Uno, T. Oyama, K. Kato, H. Kato, H. Kawakubo, O. Kawamura, M. Kusano, H. Kuwano, H. Takeuchi, Y. Toh, Y. Doki, Y. Naomoto, K. Nemoto, E. Booka, H. Matsubara, T. Miyazaki, M. Muto, A. Yanagisawa, M. Yoshida, Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: Part 2. Esophagus 16, 25–43 (2019)CrossRefPubMed
11.
Zurück zum Zitat F. Lordick, C. Mariette, K. Haustermans, R. Obermannová, D. Arnold, E.G. Committee, Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl 5), v50–v57 (2016)CrossRefPubMed F. Lordick, C. Mariette, K. Haustermans, R. Obermannová, D. Arnold, E.G. Committee, Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl 5), v50–v57 (2016)CrossRefPubMed
12.
Zurück zum Zitat J.A. Ajani, T.A. D’Amico, D.J. Bentrem, J. Chao, C. Corvera, P. Das, C.S. Denlinger, P.C. Enzinger, P. Fanta, F. Farjah, H. Gerdes, M. Gibson, R.E. Glasgow, J.A. Hayman, S. Hochwald, W.L. Hofstetter, D.H. Ilson, D. Jaroszewski, K.L. Johung, R.N. Keswani, L.R. Kleinberg, S. Leong, Q.P. Ly, K.A. Matkowskyj, M. McNamara, M.F. Mulcahy, R.K. Paluri, H. Park, K.A. Perry, J. Pimiento, G.A. Poultsides, R. Roses, V.E. Strong, G. Wiesner, C.G. Willett, C.D. Wright, N.R. McMillian, L.A. Pluchino, Esophageal and esophagogastric junction cancers. J Natl Compr Cancer Netw 17(7), 855–883 (2019) J.A. Ajani, T.A. D’Amico, D.J. Bentrem, J. Chao, C. Corvera, P. Das, C.S. Denlinger, P.C. Enzinger, P. Fanta, F. Farjah, H. Gerdes, M. Gibson, R.E. Glasgow, J.A. Hayman, S. Hochwald, W.L. Hofstetter, D.H. Ilson, D. Jaroszewski, K.L. Johung, R.N. Keswani, L.R. Kleinberg, S. Leong, Q.P. Ly, K.A. Matkowskyj, M. McNamara, M.F. Mulcahy, R.K. Paluri, H. Park, K.A. Perry, J. Pimiento, G.A. Poultsides, R. Roses, V.E. Strong, G. Wiesner, C.G. Willett, C.D. Wright, N.R. McMillian, L.A. Pluchino, Esophageal and esophagogastric junction cancers. J Natl Compr Cancer Netw 17(7), 855–883 (2019)
13.
Zurück zum Zitat T.W. Rice, D.T. Patil, E.H. Blackstone, 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: Application to clinical practice. Ann Cardiothorac Surg 6, 119–130 (2017)CrossRefPubMedPubMedCentral T.W. Rice, D.T. Patil, E.H. Blackstone, 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: Application to clinical practice. Ann Cardiothorac Surg 6, 119–130 (2017)CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat T.N. Walsh, N. Noonan, D. Hollywood, A. Kelly, N. Keeling, T.P. Hennessy, A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335, 462–467 (1996)CrossRefPubMed T.N. Walsh, N. Noonan, D. Hollywood, A. Kelly, N. Keeling, T.P. Hennessy, A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335, 462–467 (1996)CrossRefPubMed
15.
Zurück zum Zitat V. Gebski, B. Burmeister, B.M. Smithers, K. Foo, J. Zalcberg, J. Simes, Australasian Gastro-Intestinal Trials Group, Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol 8, 226–234 (2007)CrossRefPubMed V. Gebski, B. Burmeister, B.M. Smithers, K. Foo, J. Zalcberg, J. Simes, Australasian Gastro-Intestinal Trials Group, Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol 8, 226–234 (2007)CrossRefPubMed
16.
Zurück zum Zitat J. Shapiro, J.J.B. van Lanschot, M.C.C.M. Hulshof, P. van Hagen, M.I. van Berge Henegouwen, B.P.L. Wijnhoven, H.W.M. van Laarhoven, G.A.P. Nieuwenhuijzen, G.A.P. Hospers, J.J. Bonenkamp, M.A. Cuesta, R.J.B. Blaisse, O.R.C. Busch, F.J.W. Ten Kate, G.M. Creemers, C.J.A. Punt, J.T.M. Plukker, H.M.W. Verheul, E.J.S. Bilgen, H. van Dekken, M.J.C. van der Sangen, T. Rozema, K. Biermann, J.C. Beukema, A.H.M. Piet, C.M. van Rij, J.G. Reinders, H.W. Tilanus, E.W. Steyerberg, A. van der Gaast, CROSS Study Group, Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial. Lancet Oncol 16, 1090–1098 (2015)CrossRefPubMed J. Shapiro, J.J.B. van Lanschot, M.C.C.M. Hulshof, P. van Hagen, M.I. van Berge Henegouwen, B.P.L. Wijnhoven, H.W.M. van Laarhoven, G.A.P. Nieuwenhuijzen, G.A.P. Hospers, J.J. Bonenkamp, M.A. Cuesta, R.J.B. Blaisse, O.R.C. Busch, F.J.W. Ten Kate, G.M. Creemers, C.J.A. Punt, J.T.M. Plukker, H.M.W. Verheul, E.J.S. Bilgen, H. van Dekken, M.J.C. van der Sangen, T. Rozema, K. Biermann, J.C. Beukema, A.H.M. Piet, C.M. van Rij, J.G. Reinders, H.W. Tilanus, E.W. Steyerberg, A. van der Gaast, CROSS Study Group, Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial. Lancet Oncol 16, 1090–1098 (2015)CrossRefPubMed
17.
Zurück zum Zitat J. Tepper, M.J. Krasna, D. Niedzwiecki, D. Hollis, C.E. Reed, R. Goldberg, K. Kiel, C. Willett, D. Sugarbaker, R. Mayer, Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26, 1086–1092 (2008)CrossRefPubMed J. Tepper, M.J. Krasna, D. Niedzwiecki, D. Hollis, C.E. Reed, R. Goldberg, K. Kiel, C. Willett, D. Sugarbaker, R. Mayer, Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26, 1086–1092 (2008)CrossRefPubMed
18.
Zurück zum Zitat J.S. Cooper, M.D. Guo, A. Herskovic, J.S. Macdonald, J.A. Martenson, M. Al-Sarraf, R. Byhardt, A.H. Russell, J.J. Beitler, S. Spencer, S.O. Asbell, M.V. Graham, L.L. Leichman, Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281, 1623–1627 (1999)CrossRefPubMed J.S. Cooper, M.D. Guo, A. Herskovic, J.S. Macdonald, J.A. Martenson, M. Al-Sarraf, R. Byhardt, A.H. Russell, J.J. Beitler, S. Spencer, S.O. Asbell, M.V. Graham, L.L. Leichman, Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281, 1623–1627 (1999)CrossRefPubMed
19.
Zurück zum Zitat S. Paul, N. Altorki, Outcomes in the management of esophageal cancer. J Surg Oncol 110, 599–610 (2014)CrossRefPubMed S. Paul, N. Altorki, Outcomes in the management of esophageal cancer. J Surg Oncol 110, 599–610 (2014)CrossRefPubMed
20.
Zurück zum Zitat J. Chang, W. Tan, Z. Ling, R. Xi, M. Shao, M. Chen, Y. Luo, Y. Zhao, Y. Liu, X. Huang, Y. Xia, J. Hu, J.S. Parker, D. Marron, Q. Cui, L. Peng, J. Chu, H. Li, Z. Du, Y. Han, Z. Liu, Q. Zhan, Y. Li, W. Mao, C. Wu, D. Lin, Genomic analysis of oesophageal squamous-cell carcinoma identifies alcohol drinking-related mutation signature and genomic alterations. Nat Commun 8, 15290 (2017)CrossRefPubMedPubMedCentral J. Chang, W. Tan, Z. Ling, R. Xi, M. Shao, M. Chen, Y. Luo, Y. Zhao, Y. Liu, X. Huang, Y. Xia, J. Hu, J.S. Parker, D. Marron, Q. Cui, L. Peng, J. Chu, H. Li, Z. Du, Y. Han, Z. Liu, Q. Zhan, Y. Li, W. Mao, C. Wu, D. Lin, Genomic analysis of oesophageal squamous-cell carcinoma identifies alcohol drinking-related mutation signature and genomic alterations. Nat Commun 8, 15290 (2017)CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat C. Cheng, Y. Zhou, H. Li, T. Xiong, S. Li, Y. Bi, P. Kong, F. Wang, H. Cui, Y. Li, X. Fang, T. Yan, J. Wang, B. Yang, L. Zhang, Z. Jia, B. Song, X. Hu, J. Yang, H. Qiu, G. Zhang, J. Liu, E. Xu, R. Shi, Y. Zhang, H. Liu, C. He, Z. Zhao, Y. Qian, R. Rong, Z. Han, W. Luo, S. Peng, X. Yang, X. Li, L. Li, H. Fang, X. Liu, L. Ma, Y. Chen, S. Guo, X. Chen, Y. Xi, G. Li, J. Liang, J. Guo, J. Jia, Q. Li, X. Cheng, Q. Zhan, Y. Cui, Whole-genome sequencing reveals diverse models of structural variations in esophageal squamous cell carcinoma. Am J Hum Genet 98, 256–274 (2016)CrossRefPubMedPubMedCentral C. Cheng, Y. Zhou, H. Li, T. Xiong, S. Li, Y. Bi, P. Kong, F. Wang, H. Cui, Y. Li, X. Fang, T. Yan, J. Wang, B. Yang, L. Zhang, Z. Jia, B. Song, X. Hu, J. Yang, H. Qiu, G. Zhang, J. Liu, E. Xu, R. Shi, Y. Zhang, H. Liu, C. He, Z. Zhao, Y. Qian, R. Rong, Z. Han, W. Luo, S. Peng, X. Yang, X. Li, L. Li, H. Fang, X. Liu, L. Ma, Y. Chen, S. Guo, X. Chen, Y. Xi, G. Li, J. Liang, J. Guo, J. Jia, Q. Li, X. Cheng, Q. Zhan, Y. Cui, Whole-genome sequencing reveals diverse models of structural variations in esophageal squamous cell carcinoma. Am J Hum Genet 98, 256–274 (2016)CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat J. Deng, H. Chen, D. Zhou, J. Zhang, Y. Chen, Q. Liu, D. Ai, H. Zhu, L. Chu, W. Ren, X. Zhang, Y. Xia, M. Sun, H. Zhang, J. Li, X. Peng, L. Li, L. Han, H. Lin, X. Cai, J. Xiang, S. Chen, Y. Sun, Y. Zhang, S. Zhang, Y. Zhao, Y. Liu, H. Liang, K. Zhao, Comparative genomic analysis of esophageal squamous cell carcinoma between Asian and Caucasian patient populations. Nat Commun 8, 1533 (2017)CrossRefPubMedPubMedCentral J. Deng, H. Chen, D. Zhou, J. Zhang, Y. Chen, Q. Liu, D. Ai, H. Zhu, L. Chu, W. Ren, X. Zhang, Y. Xia, M. Sun, H. Zhang, J. Li, X. Peng, L. Li, L. Han, H. Lin, X. Cai, J. Xiang, S. Chen, Y. Sun, Y. Zhang, S. Zhang, Y. Zhao, Y. Liu, H. Liang, K. Zhao, Comparative genomic analysis of esophageal squamous cell carcinoma between Asian and Caucasian patient populations. Nat Commun 8, 1533 (2017)CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat J. Deng, X. Weng, J. Ye, D. Zhou, Y. Liu, K. Zhao, Identification of the germline mutation profile in esophageal squamous cell carcinoma by whole exome sequencing. Front Genet 10, 47 (2019)CrossRefPubMedPubMedCentral J. Deng, X. Weng, J. Ye, D. Zhou, Y. Liu, K. Zhao, Identification of the germline mutation profile in esophageal squamous cell carcinoma by whole exome sequencing. Front Genet 10, 47 (2019)CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat H.D. Qin, X.Y. Liao, Y.B. Chen, S.Y. Huang, W.Q. Xue, F.F. Li, X.S. Ge, D.Q. Liu, Q. Cai, J. Long, X.Z. Li, Y.Z. Hu, S.D. Zhang, L.J. Zhang, B. Lehrman, A.F. Scott, D. Lin, Y.X. Zeng, Y.Y. Shugart, W.H. Jia, Genomic characterization of esophageal squamous cell carcinoma reveals critical genes underlying tumorigenesis and poor prognosis. Am J Hum Genet 98, 709–727 (2016)CrossRefPubMedPubMedCentral H.D. Qin, X.Y. Liao, Y.B. Chen, S.Y. Huang, W.Q. Xue, F.F. Li, X.S. Ge, D.Q. Liu, Q. Cai, J. Long, X.Z. Li, Y.Z. Hu, S.D. Zhang, L.J. Zhang, B. Lehrman, A.F. Scott, D. Lin, Y.X. Zeng, Y.Y. Shugart, W.H. Jia, Genomic characterization of esophageal squamous cell carcinoma reveals critical genes underlying tumorigenesis and poor prognosis. Am J Hum Genet 98, 709–727 (2016)CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Y. Song, L. Li, Y. Ou, Z. Gao, E. Li, X. Li, W. Zhang, J. Wang, L. Xu, Y. Zhou, X. Ma, L. Liu, Z. Zhao, X. Huang, J. Fan, L. Dong, G. Chen, L. Ma, J. Yang, L. Chen, M. He, M. Li, X. Zhuang, K. Huang, K. Qiu, G. Yin, G. Guo, Q. Feng, P. Chen, Z. Wu, J. Wu, J. Zhao, L. Luo, M. Fu, B. Xu, B. Chen, Y. Li, T. Tong, M. Wang, Z. Liu, D. Lin, X. Zhang, H. Yang, Q. Zhan, Identification of genomic alterations in oesophageal squamous cell cancer. Nature 509, 91–95 (2014)CrossRefPubMed Y. Song, L. Li, Y. Ou, Z. Gao, E. Li, X. Li, W. Zhang, J. Wang, L. Xu, Y. Zhou, X. Ma, L. Liu, Z. Zhao, X. Huang, J. Fan, L. Dong, G. Chen, L. Ma, J. Yang, L. Chen, M. He, M. Li, X. Zhuang, K. Huang, K. Qiu, G. Yin, G. Guo, Q. Feng, P. Chen, Z. Wu, J. Wu, J. Zhao, L. Luo, M. Fu, B. Xu, B. Chen, Y. Li, T. Tong, M. Wang, Z. Liu, D. Lin, X. Zhang, H. Yang, Q. Zhan, Identification of genomic alterations in oesophageal squamous cell cancer. Nature 509, 91–95 (2014)CrossRefPubMed
26.
Zurück zum Zitat T. Xiong, M. Wang, J. Zhao, Q. Liu, C. Yang, W. Luo, X. Li, H. Yang, K. Kristiansen, B. Roy, Y. Zhou, An esophageal squamous cell carcinoma classification system that reveals potential targets for therapy. Oncotarget 8, 49851–49860 (2017)CrossRefPubMedPubMedCentral T. Xiong, M. Wang, J. Zhao, Q. Liu, C. Yang, W. Luo, X. Li, H. Yang, K. Kristiansen, B. Roy, Y. Zhou, An esophageal squamous cell carcinoma classification system that reveals potential targets for therapy. Oncotarget 8, 49851–49860 (2017)CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat L. Zhang, Y. Zhou, C. Cheng, H. Cui, L. Cheng, P. Kong, J. Wang, Y. Li, W. Chen, B. Song, F. Wang, Z. Jia, L. Li, B. Yang, J. Liu, R. Shi, Y. Bi, Y. Zhang, Z. Zhao, X. Hu, J. Yang, H. Li, Z. Gao, G. Chen, X. Huang, X. Yang, S. Wan, C. Chen, B. Li, Y. Tan, L. Chen, M. He, S. Xie, X. Li, X. Zhuang, M. Wang, Z. Xia, L. Luo, J. Ma, B. Dong, J. Zhao, Y. Song, Y. Ou, E. Li, L. Xu, Y. Xi, G. Li, E. Xu, J. Liang, J. Guo, X. Chen, Q. Li, L. Liu, X. Zhang, H. Yang, D. Lin, X. Cheng, Y. Guo, Q. Zhan, Y. Cui, Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. Am J Hum Genet 96, 597–611 (2015)CrossRefPubMedPubMedCentral L. Zhang, Y. Zhou, C. Cheng, H. Cui, L. Cheng, P. Kong, J. Wang, Y. Li, W. Chen, B. Song, F. Wang, Z. Jia, L. Li, B. Yang, J. Liu, R. Shi, Y. Bi, Y. Zhang, Z. Zhao, X. Hu, J. Yang, H. Li, Z. Gao, G. Chen, X. Huang, X. Yang, S. Wan, C. Chen, B. Li, Y. Tan, L. Chen, M. He, S. Xie, X. Li, X. Zhuang, M. Wang, Z. Xia, L. Luo, J. Ma, B. Dong, J. Zhao, Y. Song, Y. Ou, E. Li, L. Xu, Y. Xi, G. Li, E. Xu, J. Liang, J. Guo, X. Chen, Q. Li, L. Liu, X. Zhang, H. Yang, D. Lin, X. Cheng, Y. Guo, Q. Zhan, Y. Cui, Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. Am J Hum Genet 96, 597–611 (2015)CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat M. Hazawa, D.C. Lin, H. Handral, L. Xu, Y. Chen, Y.Y. Jiang, A. Mayakonda, L.W. Ding, X. Meng, A. Sharma, S. Samuel, M.M. Movahednia, R.W. Wong, H. Yang, C. Tong, H.P. Koeffler, ZNF750 is a lineage-specific tumour suppressor in squamous cell carcinoma. Oncogene 36, 2243–2254 (2017)CrossRefPubMed M. Hazawa, D.C. Lin, H. Handral, L. Xu, Y. Chen, Y.Y. Jiang, A. Mayakonda, L.W. Ding, X. Meng, A. Sharma, S. Samuel, M.M. Movahednia, R.W. Wong, H. Yang, C. Tong, H.P. Koeffler, ZNF750 is a lineage-specific tumour suppressor in squamous cell carcinoma. Oncogene 36, 2243–2254 (2017)CrossRefPubMed
29.
Zurück zum Zitat M. Secrier, X. Li, N. de Silva, M.D. Eldridge, G. Contino, J. Bornschein, S. MacRae, N. Grehan, M. O'Donovan, A. Miremadi, T.P. Yang, L. Bower, H. Chettouh, J. Crawte, N. Galeano-Dalmau, A. Grabowska, J. Saunders, T. Underwood, N. Waddell, A.P. Barbour, B. Nutzinger, A. Achilleos, P.A. Edwards, A.G. Lynch, S. Tavaré, R.C. Fitzgerald, Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet 48, 1131–1141 (2016)CrossRefPubMedPubMedCentral M. Secrier, X. Li, N. de Silva, M.D. Eldridge, G. Contino, J. Bornschein, S. MacRae, N. Grehan, M. O'Donovan, A. Miremadi, T.P. Yang, L. Bower, H. Chettouh, J. Crawte, N. Galeano-Dalmau, A. Grabowska, J. Saunders, T. Underwood, N. Waddell, A.P. Barbour, B. Nutzinger, A. Achilleos, P.A. Edwards, A.G. Lynch, S. Tavaré, R.C. Fitzgerald, Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet 48, 1131–1141 (2016)CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Y.J. Bang, E. Van Cutsem, A. Feyereislova, H.C. Chung, L. Shen, A. Sawaki, F. Lordick, A. Ohtsu, Y. Omuro, T. Satoh, G. Aprile, E. Kulikov, J. Hill, M. Lehle, J. Rüschoff, Y.K. Kang, T.T. Investigators, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376, 687–697 (2010)CrossRefPubMed Y.J. Bang, E. Van Cutsem, A. Feyereislova, H.C. Chung, L. Shen, A. Sawaki, F. Lordick, A. Ohtsu, Y. Omuro, T. Satoh, G. Aprile, E. Kulikov, J. Hill, M. Lehle, J. Rüschoff, Y.K. Kang, T.T. Investigators, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376, 687–697 (2010)CrossRefPubMed
31.
Zurück zum Zitat C.S. Fuchs, T. Doi, R.W. Jang, K. Muro, T. Satoh, M. Machado, W. Sun, S.I. Jalal, M.A. Shah, J.P. Metges, M. Garrido, T. Golan, M. Mandala, Z.A. Wainberg, D.V. Catenacci, A. Ohtsu, K. Shitara, R. Geva, J. Bleeker, A.H. Ko, G. Ku, P. Philip, P.C. Enzinger, Y.J. Bang, D. Levitan, J. Wang, M. Rosales, R.P. Dalal, H.H. Yoon, Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 Trial. JAMA Oncol 4, e180013 (2018)CrossRefPubMedPubMedCentral C.S. Fuchs, T. Doi, R.W. Jang, K. Muro, T. Satoh, M. Machado, W. Sun, S.I. Jalal, M.A. Shah, J.P. Metges, M. Garrido, T. Golan, M. Mandala, Z.A. Wainberg, D.V. Catenacci, A. Ohtsu, K. Shitara, R. Geva, J. Bleeker, A.H. Ko, G. Ku, P. Philip, P.C. Enzinger, Y.J. Bang, D. Levitan, J. Wang, M. Rosales, R.P. Dalal, H.H. Yoon, Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 Trial. JAMA Oncol 4, e180013 (2018)CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat C.S. Fuchs, J. Tomasek, C.J. Yong, F. Dumitru, R. Passalacqua, C. Goswami, H. Safran, L.V.D. Santos, G. Aprile, D.R. Ferry, B. Melichar, M. Tehfe, E. Topuzov, J.R. Zalcberg, I. Chau, W. Campbell, C. Sivanandan, J. Pikiel, M. Koshiji, Y. Hsu, A.M. Liepa, L. Gao, J.D. Schwartz, J. Tabernero, R.T. Investigators, Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383, 31–39 (2014)CrossRefPubMed C.S. Fuchs, J. Tomasek, C.J. Yong, F. Dumitru, R. Passalacqua, C. Goswami, H. Safran, L.V.D. Santos, G. Aprile, D.R. Ferry, B. Melichar, M. Tehfe, E. Topuzov, J.R. Zalcberg, I. Chau, W. Campbell, C. Sivanandan, J. Pikiel, M. Koshiji, Y. Hsu, A.M. Liepa, L. Gao, J.D. Schwartz, J. Tabernero, R.T. Investigators, Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383, 31–39 (2014)CrossRefPubMed
33.
Zurück zum Zitat M.A. Shah, T. Kojima, D. Hochhauser, P. Enzinger, J. Raimbourg, A. Hollebecque, F. Lordick, S.B. Kim, M. Tajika, H.T. Kim, A.C. Lockhart, H.T. Arkenau, F. El-Hajbi, M. Gupta, P. Pfeiffer, Q. Liu, J. Lunceford, S.P. Kang, P. Bhagia, K. Kato, Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: The phase 2 KEYNOTE-180 study. JAMA Oncol 5, 546-550 (2019) M.A. Shah, T. Kojima, D. Hochhauser, P. Enzinger, J. Raimbourg, A. Hollebecque, F. Lordick, S.B. Kim, M. Tajika, H.T. Kim, A.C. Lockhart, H.T. Arkenau, F. El-Hajbi, M. Gupta, P. Pfeiffer, Q. Liu, J. Lunceford, S.P. Kang, P. Bhagia, K. Kato, Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: The phase 2 KEYNOTE-180 study. JAMA Oncol 5, 546-550 (2019)
34.
Zurück zum Zitat H. Wilke, K. Muro, E. Van Cutsem, S.C. Oh, G. Bodoky, Y. Shimada, S. Hironaka, N. Sugimoto, O. Lipatov, T.Y. Kim, D. Cunningham, P. Rougier, Y. Komatsu, J. Ajani, M. Emig, R. Carlesi, D. Ferry, K. Chandrawansa, J.D. Schwartz, A. Ohtsu, RAINBOW Study Group, Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol 15, 1224–1235 (2014)CrossRefPubMed H. Wilke, K. Muro, E. Van Cutsem, S.C. Oh, G. Bodoky, Y. Shimada, S. Hironaka, N. Sugimoto, O. Lipatov, T.Y. Kim, D. Cunningham, P. Rougier, Y. Komatsu, J. Ajani, M. Emig, R. Carlesi, D. Ferry, K. Chandrawansa, J.D. Schwartz, A. Ohtsu, RAINBOW Study Group, Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol 15, 1224–1235 (2014)CrossRefPubMed
35.
Zurück zum Zitat S. Kasper, M. Schuler, Targeted therapies in gastroesophageal cancer. Eur J Cancer 50, 1247–1258 (2014)CrossRefPubMed S. Kasper, M. Schuler, Targeted therapies in gastroesophageal cancer. Eur J Cancer 50, 1247–1258 (2014)CrossRefPubMed
36.
Zurück zum Zitat P. Samson, A.C. Lockhart, Biologic therapy in esophageal and gastric malignancies: Current therapies and future directions. J Gastrointest Oncol 8, 418–429 (2017)CrossRefPubMedPubMedCentral P. Samson, A.C. Lockhart, Biologic therapy in esophageal and gastric malignancies: Current therapies and future directions. J Gastrointest Oncol 8, 418–429 (2017)CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat J. Tabernero, P.M. Hoff, L. Shen, A. Ohtsu, M.A. Shah, K. Cheng, C. Song, H. Wu, J. Eng-Wong, K. Kim, Y.K. Kang, Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): Final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol 19, 1372–1384 (2018)CrossRefPubMed J. Tabernero, P.M. Hoff, L. Shen, A. Ohtsu, M.A. Shah, K. Cheng, C. Song, H. Wu, J. Eng-Wong, K. Kim, Y.K. Kang, Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): Final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol 19, 1372–1384 (2018)CrossRefPubMed
38.
Zurück zum Zitat P.C. Thuss-Patience, M.A. Shah, A. Ohtsu, E. Van Cutsem, J.A. Ajani, H. Castro, W. Mansoor, H.C. Chung, G. Bodoky, K. Shitara, G.D.L. Phillips, T. van der Horst, M.L. Harle-Yge, B.L. Althaus, Y.K. Kang, Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): An international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol 18, 640–653 (2017)CrossRefPubMed P.C. Thuss-Patience, M.A. Shah, A. Ohtsu, E. Van Cutsem, J.A. Ajani, H. Castro, W. Mansoor, H.C. Chung, G. Bodoky, K. Shitara, G.D.L. Phillips, T. van der Horst, M.L. Harle-Yge, B.L. Althaus, Y.K. Kang, Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): An international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol 18, 640–653 (2017)CrossRefPubMed
39.
Zurück zum Zitat T. Waddell, I. Chau, D. Cunningham, D. Gonzalez, A.F. Okines, A. Frances, C. Okines, A. Wotherspoon, C. Saffery, G. Middleton, J. Wadsley, D. Ferry, W. Mansoor, T. Crosby, F. Coxon, D. Smith, J. Waters, T. Iveson, S. Falk, S. Slater, C. Peckitt, Y. Barbachano, Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): A randomised, open-label phase 3 trial. Lancet Oncol 14, 481–489 (2013)CrossRefPubMedPubMedCentral T. Waddell, I. Chau, D. Cunningham, D. Gonzalez, A.F. Okines, A. Frances, C. Okines, A. Wotherspoon, C. Saffery, G. Middleton, J. Wadsley, D. Ferry, W. Mansoor, T. Crosby, F. Coxon, D. Smith, J. Waters, T. Iveson, S. Falk, S. Slater, C. Peckitt, Y. Barbachano, Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): A randomised, open-label phase 3 trial. Lancet Oncol 14, 481–489 (2013)CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat N. Mavaddat, D. Barrowdale, I.L. Andrulis, S.M. Domchek, D. Eccles, H. Nevanlinna, S.J. Ramus, A. Spurdle, M. Robson, M. Sherman, A.M. Mulligan, F.J. Couch, C. Engel, L. McGuffog, S. Healey, O.M. Sinilnikova, M.C. Southey, M.B. Terry, D. Goldgar, F. O'Malley, E.M. John, R. Janavicius, L. Tihomirova, T.V. Hansen, F.C. Nielsen, A. Osorio, A. Stavropoulou, J. Benítez, S. Manoukian, B. Peissel, M. Barile, S. Volorio, B. Pasini, R. Dolcetti, A.L. Putignano, L. Ottini, P. Radice, U. Hamann, M.U. Rashid, F.B. Hogervorst, M. Kriege, R.B. van der Luijt, S. Peock, D. Frost, D.G. Evans, C. Brewer, L. Walker, M.T. Rogers, L.E. Side, C. Houghton, J. Weaver, A.K. Godwin, R.K. Schmutzler, B. Wappenschmidt, A. Meindl, K. Kast, N. Arnold, D. Niederacher, C. Sutter, H. Deissler, D. Gadzicki, S. Preisler-Adams, R. Varon-Mateeva, I. Schönbuchner, H. Gevensleben, D. Stoppa-Lyonnet, M. Belotti, L. Barjhoux, C. Isaacs, B.N. Peshkin, T. Caldes, M. de la Hoya, C. Cañadas, T. Heikkinen, P. Heikkilä, K. Aittomäki, I. Blanco, C. Lazaro, J. Brunet, B.A. Agnarsson, A. Arason, R.B. Barkardottir, M. Dumont, J. Simard, M. Montagna, S. Agata, E. D'Andrea, M. Yan, S. Fox, T.R. Rebbeck, W. Rubinstein, N. Tung, J.E. Garber, X. Wang, Z. Fredericksen, V.S. Pankratz, N.M. Lindor, C. Szabo, K. Offit, R. Sakr, M.M. Gaudet, C.F. Singer, M.K. Tea, C. Rappaport, P.L. Mai, M.H. Greene, A. Sokolenko, E. Imyanitov, A.E. Toland, L. Senter, K. Sweet, M. Thomassen, A.M. Gerdes, T. Kruse, M. Caligo, P. Aretini, J. Rantala, A. von Wachenfeld, K. Henriksson, L. Steele, S.L. Neuhausen, R. Nussbaum, M. Beattie, K. Odunsi, L. Sucheston, S.A. Gayther, K. Nathanson, J. Gross, C. Walsh, B. Karlan, G. Chenevix-Trench, D.F. Easton, A.C. Antoniou, HEBON, EMBRACE, GEMO Study Collaborators, kConFab Investigators, SWE-BRCA Collaborators and Consortium of Investigators of Modifiers of BRCA1/2, Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 21, 134–147 (2012)CrossRefPubMed N. Mavaddat, D. Barrowdale, I.L. Andrulis, S.M. Domchek, D. Eccles, H. Nevanlinna, S.J. Ramus, A. Spurdle, M. Robson, M. Sherman, A.M. Mulligan, F.J. Couch, C. Engel, L. McGuffog, S. Healey, O.M. Sinilnikova, M.C. Southey, M.B. Terry, D. Goldgar, F. O'Malley, E.M. John, R. Janavicius, L. Tihomirova, T.V. Hansen, F.C. Nielsen, A. Osorio, A. Stavropoulou, J. Benítez, S. Manoukian, B. Peissel, M. Barile, S. Volorio, B. Pasini, R. Dolcetti, A.L. Putignano, L. Ottini, P. Radice, U. Hamann, M.U. Rashid, F.B. Hogervorst, M. Kriege, R.B. van der Luijt, S. Peock, D. Frost, D.G. Evans, C. Brewer, L. Walker, M.T. Rogers, L.E. Side, C. Houghton, J. Weaver, A.K. Godwin, R.K. Schmutzler, B. Wappenschmidt, A. Meindl, K. Kast, N. Arnold, D. Niederacher, C. Sutter, H. Deissler, D. Gadzicki, S. Preisler-Adams, R. Varon-Mateeva, I. Schönbuchner, H. Gevensleben, D. Stoppa-Lyonnet, M. Belotti, L. Barjhoux, C. Isaacs, B.N. Peshkin, T. Caldes, M. de la Hoya, C. Cañadas, T. Heikkinen, P. Heikkilä, K. Aittomäki, I. Blanco, C. Lazaro, J. Brunet, B.A. Agnarsson, A. Arason, R.B. Barkardottir, M. Dumont, J. Simard, M. Montagna, S. Agata, E. D'Andrea, M. Yan, S. Fox, T.R. Rebbeck, W. Rubinstein, N. Tung, J.E. Garber, X. Wang, Z. Fredericksen, V.S. Pankratz, N.M. Lindor, C. Szabo, K. Offit, R. Sakr, M.M. Gaudet, C.F. Singer, M.K. Tea, C. Rappaport, P.L. Mai, M.H. Greene, A. Sokolenko, E. Imyanitov, A.E. Toland, L. Senter, K. Sweet, M. Thomassen, A.M. Gerdes, T. Kruse, M. Caligo, P. Aretini, J. Rantala, A. von Wachenfeld, K. Henriksson, L. Steele, S.L. Neuhausen, R. Nussbaum, M. Beattie, K. Odunsi, L. Sucheston, S.A. Gayther, K. Nathanson, J. Gross, C. Walsh, B. Karlan, G. Chenevix-Trench, D.F. Easton, A.C. Antoniou, HEBON, EMBRACE, GEMO Study Collaborators, kConFab Investigators, SWE-BRCA Collaborators and Consortium of Investigators of Modifiers of BRCA1/2, Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 21, 134–147 (2012)CrossRefPubMed
41.
Zurück zum Zitat A.D. Wagner, H.I. Grabsch, M. Mauer, S. Marreaud, C. Caballero, P. Thuss-Patience, L. Mueller, A. Elme, M.H. Moehler, U. Martens, Y.K. Kang, S.Y. Rha, A. Cats, M. Tokunaga, F. Lordick, EORTC-1203-GITCG – The “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: A randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer 19, 494 (2019)CrossRefPubMedPubMedCentral A.D. Wagner, H.I. Grabsch, M. Mauer, S. Marreaud, C. Caballero, P. Thuss-Patience, L. Mueller, A. Elme, M.H. Moehler, U. Martens, Y.K. Kang, S.Y. Rha, A. Cats, M. Tokunaga, F. Lordick, EORTC-1203-GITCG – The “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: A randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer 19, 494 (2019)CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat J.R. Hecht, Y.J. Bang, S.K. Qin, H.C. Chung, J.M. Xu, J.O. Park, K. Jeziorski, Y. Shparyk, P.M. Hoff, A. Sobrero, P. Salman, J. Li, S.A. Protsenko, Z.A. Wainberg, M. Buyse, K. Afenjar, V. Houé, A. Garcia, T. Kaneko, Y. Huang, S. Khan-Wasti, S. Santillana, M.F. Press, D. Slamon, Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC – A randomized phase III trial. J Clin Oncol 34, 443–451 (2016)CrossRefPubMed J.R. Hecht, Y.J. Bang, S.K. Qin, H.C. Chung, J.M. Xu, J.O. Park, K. Jeziorski, Y. Shparyk, P.M. Hoff, A. Sobrero, P. Salman, J. Li, S.A. Protsenko, Z.A. Wainberg, M. Buyse, K. Afenjar, V. Houé, A. Garcia, T. Kaneko, Y. Huang, S. Khan-Wasti, S. Santillana, M.F. Press, D. Slamon, Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC – A randomized phase III trial. J Clin Oncol 34, 443–451 (2016)CrossRefPubMed
44.
Zurück zum Zitat A. Ghahremanloo, A. Soltani, S.M.S. Modaresi, S.I. Hashemy, Recent advances in the clinical development of immune checkpoint blockade therapy. Cell Oncol 42, 609–626 (2019)CrossRef A. Ghahremanloo, A. Soltani, S.M.S. Modaresi, S.I. Hashemy, Recent advances in the clinical development of immune checkpoint blockade therapy. Cell Oncol 42, 609–626 (2019)CrossRef
45.
Zurück zum Zitat L. Fashoyin-Aje, M. Donoghue, H. Chen, K. He, J. Veeraraghavan, K.B. Goldberg, P. Keegan, A.E. McKee, R. Pazdur, FDA approval summary: Pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1. Oncologist 24, 103–109 (2019)CrossRefPubMed L. Fashoyin-Aje, M. Donoghue, H. Chen, K. He, J. Veeraraghavan, K.B. Goldberg, P. Keegan, A.E. McKee, R. Pazdur, FDA approval summary: Pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1. Oncologist 24, 103–109 (2019)CrossRefPubMed
48.
Zurück zum Zitat K. Shitara, M. Özgüroğlu, Y.J. Bang, M. Di Bartolomeo, M. Mandalà, M.H. Ryu, L. Fornaro, T. Olesiński, C. Caglevic, H.C. Chung, K. Muro, E. Goekkurt, W. Mansoor, R.S. McDermott, E. Shacham-Shmueli, X. Chen, C. Mayo, S.P. Kang, A. Ohtsu, C.S. Fuchs, KEYNOTE-061 Investigators, Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): A randomised, open-label, controlled, phase 3 trial. Lancet 392, 123–133 (2018)CrossRefPubMed K. Shitara, M. Özgüroğlu, Y.J. Bang, M. Di Bartolomeo, M. Mandalà, M.H. Ryu, L. Fornaro, T. Olesiński, C. Caglevic, H.C. Chung, K. Muro, E. Goekkurt, W. Mansoor, R.S. McDermott, E. Shacham-Shmueli, X. Chen, C. Mayo, S.P. Kang, A. Ohtsu, C.S. Fuchs, KEYNOTE-061 Investigators, Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): A randomised, open-label, controlled, phase 3 trial. Lancet 392, 123–133 (2018)CrossRefPubMed
49.
Zurück zum Zitat Y.K. Kang, N. Boku, T. Satoh, M.H. Ryu, Y. Chao, K. Kato, H.C. Chung, J.S. Chen, K. Muro, W.K. Kang, K.H. Yeh, T. Yoshikawa, S.C. Oh, L.Y. Bai, T. Tamura, K.W. Lee, Y. Hamamoto, J.G. Kim, K. Chin, D.Y. Oh, K. Minashi, J.Y. Cho, M. Tsuda, L.T. Chen, Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 2461–2471 (2017)CrossRefPubMed Y.K. Kang, N. Boku, T. Satoh, M.H. Ryu, Y. Chao, K. Kato, H.C. Chung, J.S. Chen, K. Muro, W.K. Kang, K.H. Yeh, T. Yoshikawa, S.C. Oh, L.Y. Bai, T. Tamura, K.W. Lee, Y. Hamamoto, J.G. Kim, K. Chin, D.Y. Oh, K. Minashi, J.Y. Cho, M. Tsuda, L.T. Chen, Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 2461–2471 (2017)CrossRefPubMed
50.
Zurück zum Zitat N. Boku, M.H. Ryu, K. Kato, H.C. Chung, K. Minashi, K.W. Lee, H. Cho, W.K. Kang, Y. Komatsu, M. Tsuda, K. Yamaguchi, H. Hara, S. Fumita, M. Azuma, L.T. Chen, Y.K. Kang, Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol 30, 250–258 (2019)CrossRefPubMed N. Boku, M.H. Ryu, K. Kato, H.C. Chung, K. Minashi, K.W. Lee, H. Cho, W.K. Kang, Y. Komatsu, M. Tsuda, K. Yamaguchi, H. Hara, S. Fumita, M. Azuma, L.T. Chen, Y.K. Kang, Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol 30, 250–258 (2019)CrossRefPubMed
51.
Zurück zum Zitat Y.J. Bang, E.Y. Ruiz, E. Van Cutsem, K.W. Lee, L. Wyrwicz, M. Schenker, M. Alsina, M.H. Ryu, H.C. Chung, L. Evesque, S.E. Al-Batran, S.H. Park, M. Lichinitser, N. Boku, M.H. Moehler, J. Hong, H. Xiong, R. Hallwachs, I. Conti, J. Taieb, Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: Primary analysis of JAVELIN Gastric 300. Ann Oncol 29, 2052–2060 (2018)CrossRefPubMedPubMedCentral Y.J. Bang, E.Y. Ruiz, E. Van Cutsem, K.W. Lee, L. Wyrwicz, M. Schenker, M. Alsina, M.H. Ryu, H.C. Chung, L. Evesque, S.E. Al-Batran, S.H. Park, M. Lichinitser, N. Boku, M.H. Moehler, J. Hong, H. Xiong, R. Hallwachs, I. Conti, J. Taieb, Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: Primary analysis of JAVELIN Gastric 300. Ann Oncol 29, 2052–2060 (2018)CrossRefPubMedPubMedCentral
52.
Zurück zum Zitat Y.J. Bang, J.Y. Cho, Y.H. Kim, J.W. Kim, M. Di Bartolomeo, J.A. Ajani, K. Yamaguchi, A. Balogh, T. Sanchez, M. Moehler, Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer. Clin Cancer Res 23, 5671–5678 (2017)CrossRefPubMed Y.J. Bang, J.Y. Cho, Y.H. Kim, J.W. Kim, M. Di Bartolomeo, J.A. Ajani, K. Yamaguchi, A. Balogh, T. Sanchez, M. Moehler, Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer. Clin Cancer Res 23, 5671–5678 (2017)CrossRefPubMed
53.
Zurück zum Zitat Y.Y. Janjigian, J. Bendell, E. Calvo, J.W. Kim, P.A. Ascierto, P. Sharma, P.A. Ott, K. Peltola, D. Jaeger, J. Evans, F. de Braud, I. Chau, C.T. Harbison, C. Dorange, M. Tschaika, D.T. Le, CheckMate-032 study: Efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol 36, 2836–2844 (2018)CrossRefPubMedPubMedCentral Y.Y. Janjigian, J. Bendell, E. Calvo, J.W. Kim, P.A. Ascierto, P. Sharma, P.A. Ott, K. Peltola, D. Jaeger, J. Evans, F. de Braud, I. Chau, C.T. Harbison, C. Dorange, M. Tschaika, D.T. Le, CheckMate-032 study: Efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol 36, 2836–2844 (2018)CrossRefPubMedPubMedCentral
57.
Zurück zum Zitat D.N. Ionescu, M.R. Downes, A. Christofides, M.S. Tsao, Harmonization of PD-L1 testing in oncology: A Canadian pathology perspective. Curr Oncol 25, e209–e216 (2018)CrossRefPubMedPubMedCentral D.N. Ionescu, M.R. Downes, A. Christofides, M.S. Tsao, Harmonization of PD-L1 testing in oncology: A Canadian pathology perspective. Curr Oncol 25, e209–e216 (2018)CrossRefPubMedPubMedCentral
58.
Zurück zum Zitat H. Polioudaki, A. Chantziou, K. Kalyvianaki, P. Malamos, G. Notas, D. Mavroudis, M. Kampa, E. Castanas, P.A. Theodoropoulos, Nuclear localization of PD-L1: Artifact or reality? Cell Oncol 42, 237–242 (2019)CrossRef H. Polioudaki, A. Chantziou, K. Kalyvianaki, P. Malamos, G. Notas, D. Mavroudis, M. Kampa, E. Castanas, P.A. Theodoropoulos, Nuclear localization of PD-L1: Artifact or reality? Cell Oncol 42, 237–242 (2019)CrossRef
59.
60.
Zurück zum Zitat C. Luchini, F. Bibeau, M.J.L. Ligtenberg, N. Singh, A. Nottegar, T. Bosse, R. Miller, N. Riaz, J.Y. Douillard, F. Andre, A. Scarpa, ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: A systematic review-based approach. Ann Oncol, doi: 10.1093/annonc/mdz116 (2019) C. Luchini, F. Bibeau, M.J.L. Ligtenberg, N. Singh, A. Nottegar, T. Bosse, R. Miller, N. Riaz, J.Y. Douillard, F. Andre, A. Scarpa, ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: A systematic review-based approach. Ann Oncol, doi: 10.1093/annonc/mdz116 (2019)
61.
Zurück zum Zitat F. Schettini, I. De Santo, C.G. Rea, P. De Placido, L. Formisano, M. Giuliano, G. Arpino, M. De Laurentiis, F. Puglisi, S. De Placido, L. Del Mastro, CDK 4/6 inhibitors as single agent in advanced solid tumors. Front Oncol 8, 608 (2018)CrossRefPubMedPubMedCentral F. Schettini, I. De Santo, C.G. Rea, P. De Placido, L. Formisano, M. Giuliano, G. Arpino, M. De Laurentiis, F. Puglisi, S. De Placido, L. Del Mastro, CDK 4/6 inhibitors as single agent in advanced solid tumors. Front Oncol 8, 608 (2018)CrossRefPubMedPubMedCentral
62.
Zurück zum Zitat L. Chen, J. Pan, Dual cyclin-dependent kinase 4/6 inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells. Br J Pharmacol 174, 2427–2443 (2017)CrossRefPubMedPubMedCentral L. Chen, J. Pan, Dual cyclin-dependent kinase 4/6 inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells. Br J Pharmacol 174, 2427–2443 (2017)CrossRefPubMedPubMedCentral
66.
Zurück zum Zitat G. Sawada, A. Niida, R. Uchi, H. Hirata, T. Shimamura, Y. Suzuki, Y. Shiraishi, K. Chiba, S. Imoto, Y. Takahashi, T. Iwaya, T. Sudo, T. Hayashi, H. Takai, Y. Kawasaki, T. Matsukawa, H. Eguchi, K. Sugimachi, F. Tanaka, H. Suzuki, K. Yamamoto, H. Ishii, M. Shimizu, H. Yamazaki, M. Yamazaki, Y. Tachimori, Y. Kajiyama, S. Natsugoe, H. Fujita, K. Mafune, Y. Tanaka, D.P. Kelsell, C.A. Scott, S. Tsuji, S. Yachida, T. Shibata, S. Sugano, Y. Doki, T. Akiyama, H. Aburatani, S. Ogawa, S. Miyano, M. Mori, K. Mimori, Genomic landscape of esophageal squamous cell carcinoma in a Japanese population. Gastroenterology 150, 1171–1182 (2016)CrossRefPubMed G. Sawada, A. Niida, R. Uchi, H. Hirata, T. Shimamura, Y. Suzuki, Y. Shiraishi, K. Chiba, S. Imoto, Y. Takahashi, T. Iwaya, T. Sudo, T. Hayashi, H. Takai, Y. Kawasaki, T. Matsukawa, H. Eguchi, K. Sugimachi, F. Tanaka, H. Suzuki, K. Yamamoto, H. Ishii, M. Shimizu, H. Yamazaki, M. Yamazaki, Y. Tachimori, Y. Kajiyama, S. Natsugoe, H. Fujita, K. Mafune, Y. Tanaka, D.P. Kelsell, C.A. Scott, S. Tsuji, S. Yachida, T. Shibata, S. Sugano, Y. Doki, T. Akiyama, H. Aburatani, S. Ogawa, S. Miyano, M. Mori, K. Mimori, Genomic landscape of esophageal squamous cell carcinoma in a Japanese population. Gastroenterology 150, 1171–1182 (2016)CrossRefPubMed
67.
Zurück zum Zitat N. Wakabayashi, K. Itoh, J. Wakabayashi, H. Motohashi, S. Noda, S. Takahashi, S. Imakado, T. Kotsuji, F. Otsuka, D.R. Roop, T. Harada, J.D. Engel, M. Yamamoto, Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat Genet 35, 238–245 (2003)CrossRefPubMed N. Wakabayashi, K. Itoh, J. Wakabayashi, H. Motohashi, S. Noda, S. Takahashi, S. Imakado, T. Kotsuji, F. Otsuka, D.R. Roop, T. Harada, J.D. Engel, M. Yamamoto, Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat Genet 35, 238–245 (2003)CrossRefPubMed
68.
Zurück zum Zitat Y. Kawasaki, H. Okumura, Y. Uchikado, Y. Kita, K. Sasaki, T. Owaki, S. Ishigami, S. Natsugoe, Nrf2 is useful for predicting the effect of chemoradiation therapy on esophageal squamous cell carcinoma. Ann Surg Oncol 21, 2347–2352 (2014)CrossRefPubMed Y. Kawasaki, H. Okumura, Y. Uchikado, Y. Kita, K. Sasaki, T. Owaki, S. Ishigami, S. Natsugoe, Nrf2 is useful for predicting the effect of chemoradiation therapy on esophageal squamous cell carcinoma. Ann Surg Oncol 21, 2347–2352 (2014)CrossRefPubMed
69.
Zurück zum Zitat T. Shibata, A. Kokubu, S. Saito, M. Narisawa-Saito, H. Sasaki, K. Aoyagi, Y. Yoshimatsu, Y. Tachimori, R. Kushima, T. Kiyono, M. Yamamoto, NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia 13, 864–873 (2011)CrossRefPubMedPubMedCentral T. Shibata, A. Kokubu, S. Saito, M. Narisawa-Saito, H. Sasaki, K. Aoyagi, Y. Yoshimatsu, Y. Tachimori, R. Kushima, T. Kiyono, M. Yamamoto, NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia 13, 864–873 (2011)CrossRefPubMedPubMedCentral
70.
Zurück zum Zitat J. Zhang, Q. Jiao, L. Kong, J. Yu, A. Fang, M. Li, Nrf2 and Keap1 abnormalities in esophageal squamous cell carcinoma and association with the effect of chemoradiotherapy. Thorac Cancer 9, 726–735 (2018)CrossRefPubMedPubMedCentral J. Zhang, Q. Jiao, L. Kong, J. Yu, A. Fang, M. Li, Nrf2 and Keap1 abnormalities in esophageal squamous cell carcinoma and association with the effect of chemoradiotherapy. Thorac Cancer 9, 726–735 (2018)CrossRefPubMedPubMedCentral
71.
Zurück zum Zitat C. Gorrini, P.S. Baniasadi, I.S. Harris, J. Silvester, S. Inoue, B. Snow, P.A. Joshi, A. Wakeham, S.D. Molyneux, B. Martin, P. Bouwman, D.W. Cescon, A.J. Elia, Z. Winterton-Perks, J. Cruickshank, D. Brenner, A. Tseng, M. Musgrave, H.K. Berman, R. Khokha, J. Jonkers, T.W. Mak, M.L. Gauthier, BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. J Exp Med 210, 1529–1544 (2013)CrossRefPubMedPubMedCentral C. Gorrini, P.S. Baniasadi, I.S. Harris, J. Silvester, S. Inoue, B. Snow, P.A. Joshi, A. Wakeham, S.D. Molyneux, B. Martin, P. Bouwman, D.W. Cescon, A.J. Elia, Z. Winterton-Perks, J. Cruickshank, D. Brenner, A. Tseng, M. Musgrave, H.K. Berman, R. Khokha, J. Jonkers, T.W. Mak, M.L. Gauthier, BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. J Exp Med 210, 1529–1544 (2013)CrossRefPubMedPubMedCentral
72.
Zurück zum Zitat S. Ma, C. Paiboonrungruan, T. Yan, K.P. Williams, M.B. Major, X.L. Chen, Targeted therapy of esophageal squamous cell carcinoma: The NRF2 signaling pathway as target. Ann N Y Acad Sci 1434, 164–172 (2018)CrossRefPubMedPubMedCentral S. Ma, C. Paiboonrungruan, T. Yan, K.P. Williams, M.B. Major, X.L. Chen, Targeted therapy of esophageal squamous cell carcinoma: The NRF2 signaling pathway as target. Ann N Y Acad Sci 1434, 164–172 (2018)CrossRefPubMedPubMedCentral
73.
Zurück zum Zitat M. Seervi, S. Sumi, A. Chandrasekharan, A.K. Sharma, T.R. SanthoshKumar, Molecular profiling of anastatic cancer cells: Potential role of the nuclear export pathway. Cell Oncol 42, 645–661 (2019)CrossRef M. Seervi, S. Sumi, A. Chandrasekharan, A.K. Sharma, T.R. SanthoshKumar, Molecular profiling of anastatic cancer cells: Potential role of the nuclear export pathway. Cell Oncol 42, 645–661 (2019)CrossRef
74.
Zurück zum Zitat A. Mizumoto, S. Ohashi, M. Kamada, T. Saito, Y. Nakai, K. Baba, K. Hirohashi, Y. Mitani, O. Kikuchi, J. Matsubara, A. Yamada, T. Takahashi, H. Lee, Y. Okuno, M. Kanai, M. Muto, Combination treatment with highly bioavailable curcumin and NQO1 inhibitor exhibits potent antitumor effects on esophageal squamous cell carcinoma. J Gastroenterol 54, 687-698 (2019) A. Mizumoto, S. Ohashi, M. Kamada, T. Saito, Y. Nakai, K. Baba, K. Hirohashi, Y. Mitani, O. Kikuchi, J. Matsubara, A. Yamada, T. Takahashi, H. Lee, Y. Okuno, M. Kanai, M. Muto, Combination treatment with highly bioavailable curcumin and NQO1 inhibitor exhibits potent antitumor effects on esophageal squamous cell carcinoma. J Gastroenterol 54, 687-698 (2019)
75.
Zurück zum Zitat T. Yan, H. Cui, Y. Zhou, B. Yang, P. Kong, Y. Zhang, Y. Liu, B. Wang, Y. Cheng, J. Li, S. Guo, E. Xu, H. Liu, C. Cheng, L. Zhang, L. Chen, X. Zhuang, Y. Qian, J. Yang, Y. Ma, H. Li, F. Wang, J. Liu, X. Liu, D. Su, Y. Wang, R. Sun, Y. Li, X. Cheng, Z. Liu, Q. Zhan, Y. Cui, Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma. Nat Commun 10, 1670 (2019)CrossRefPubMedPubMedCentral T. Yan, H. Cui, Y. Zhou, B. Yang, P. Kong, Y. Zhang, Y. Liu, B. Wang, Y. Cheng, J. Li, S. Guo, E. Xu, H. Liu, C. Cheng, L. Zhang, L. Chen, X. Zhuang, Y. Qian, J. Yang, Y. Ma, H. Li, F. Wang, J. Liu, X. Liu, D. Su, Y. Wang, R. Sun, Y. Li, X. Cheng, Z. Liu, Q. Zhan, Y. Cui, Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma. Nat Commun 10, 1670 (2019)CrossRefPubMedPubMedCentral
76.
Zurück zum Zitat A. Ashworth, C.J. Lord, Synthetic lethal therapies for cancer: What’s next after PARP inhibitors? Nat Rev Clin Oncol 15, 564–576 (2018)CrossRefPubMed A. Ashworth, C.J. Lord, Synthetic lethal therapies for cancer: What’s next after PARP inhibitors? Nat Rev Clin Oncol 15, 564–576 (2018)CrossRefPubMed
77.
Zurück zum Zitat J.K. Litton, H.S. Rugo, J. Ettl, S.A. Hurvitz, A. Gonçalves, K.H. Lee, L. Fehrenbacher, R. Yerushalmi, L.A. Mina, M. Martin, H. Roché, Y.H. Im, R.G.W. Quek, D. Markova, I.C. Tudor, A.L. Hannah, W. Eiermann, J.L. Blum, Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379, 753–763 (2018)CrossRefPubMed J.K. Litton, H.S. Rugo, J. Ettl, S.A. Hurvitz, A. Gonçalves, K.H. Lee, L. Fehrenbacher, R. Yerushalmi, L.A. Mina, M. Martin, H. Roché, Y.H. Im, R.G.W. Quek, D. Markova, I.C. Tudor, A.L. Hannah, W. Eiermann, J.L. Blum, Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379, 753–763 (2018)CrossRefPubMed
78.
Zurück zum Zitat M. Robson, C. Goessl, S. Domchek, Olaparib for metastatic germline BRCA-mutated breast cancer. N Engl J Med 377, 1792–1793 (2017)CrossRefPubMed M. Robson, C. Goessl, S. Domchek, Olaparib for metastatic germline BRCA-mutated breast cancer. N Engl J Med 377, 1792–1793 (2017)CrossRefPubMed
80.
Zurück zum Zitat K. Miyamoto, T. Minegaki, M. Tanahashi, A. Yamamoto, Y. Moriyama, A. Wada, A. Matsumoto, K. Ota, M. Tanaka, U. Masuda, M. Tsujimoto, K. Nishiguchi, Synergistic effects of olaparib and DNA-damaging agents in oesophageal squamous cell carcinoma cell lines. Anticancer Res 39, 1813–1820 (2019)CrossRefPubMed K. Miyamoto, T. Minegaki, M. Tanahashi, A. Yamamoto, Y. Moriyama, A. Wada, A. Matsumoto, K. Ota, M. Tanaka, U. Masuda, M. Tsujimoto, K. Nishiguchi, Synergistic effects of olaparib and DNA-damaging agents in oesophageal squamous cell carcinoma cell lines. Anticancer Res 39, 1813–1820 (2019)CrossRefPubMed
83.
Zurück zum Zitat A. Long, V. Giroux, K.A. Whelan, K.E. Hamilton, M.P. Tétreault, K. Tanaka, J.S. Lee, A.J. Klein-Szanto, H. Nakagawa, A.K. Rustgi, WNT10A promotes an invasive and self-renewing phenotype in esophageal squamous cell carcinoma. Carcinogenesis. 36, 598–606 (2015)CrossRefPubMedPubMedCentral A. Long, V. Giroux, K.A. Whelan, K.E. Hamilton, M.P. Tétreault, K. Tanaka, J.S. Lee, A.J. Klein-Szanto, H. Nakagawa, A.K. Rustgi, WNT10A promotes an invasive and self-renewing phenotype in esophageal squamous cell carcinoma. Carcinogenesis. 36, 598–606 (2015)CrossRefPubMedPubMedCentral
84.
Zurück zum Zitat S.H. Yang, S.L. Li, Z.M. Dong, Q.C. Kan, Epigenetic inactivation of Wnt inhibitory factor-1 in human esophageal squamous cell carcinoma. Oncol Res 20, 123–130 (2012)CrossRefPubMed S.H. Yang, S.L. Li, Z.M. Dong, Q.C. Kan, Epigenetic inactivation of Wnt inhibitory factor-1 in human esophageal squamous cell carcinoma. Oncol Res 20, 123–130 (2012)CrossRefPubMed
86.
Zurück zum Zitat A.M. Frankell, S. Jammula, X. Li, G. Contino, S. Killcoyne, S. Abbas, J. Perner, L. Bower, G. Devonshire, E. Ococks, N. Grehan, J. Mok, M. O'Donovan, S. MacRae, M.D. Eldridge, S. Tavaré, R.C. Fitzgerald, Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic. Nat Genet 51, 506–516 (2019)CrossRefPubMedPubMedCentral A.M. Frankell, S. Jammula, X. Li, G. Contino, S. Killcoyne, S. Abbas, J. Perner, L. Bower, G. Devonshire, E. Ococks, N. Grehan, J. Mok, M. O'Donovan, S. MacRae, M.D. Eldridge, S. Tavaré, R.C. Fitzgerald, Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic. Nat Genet 51, 506–516 (2019)CrossRefPubMedPubMedCentral
87.
Zurück zum Zitat G. Clément, D.M. Jablons, J. Benhattar, Targeting the Wnt signaling pathway to treat Barrett's esophagus. Expert Opin Ther Targets 11, 375–389 (2007)CrossRefPubMed G. Clément, D.M. Jablons, J. Benhattar, Targeting the Wnt signaling pathway to treat Barrett's esophagus. Expert Opin Ther Targets 11, 375–389 (2007)CrossRefPubMed
88.
Zurück zum Zitat O. Lyros, P. Rafiee, L. Nie, R. Medda, N. Jovanovic, M.F. Otterson, B. Behmaram, I. Gockel, A. Mackinnon, R. Shaker, Wnt/β-catenin signaling activation beyond robust nuclear β-catenin accumulation in nondysplastic Barrett’s esophagus: Regulation via Dickkopf-1. Neoplasia 17, 598–611 (2015)CrossRefPubMedPubMedCentral O. Lyros, P. Rafiee, L. Nie, R. Medda, N. Jovanovic, M.F. Otterson, B. Behmaram, I. Gockel, A. Mackinnon, R. Shaker, Wnt/β-catenin signaling activation beyond robust nuclear β-catenin accumulation in nondysplastic Barrett’s esophagus: Regulation via Dickkopf-1. Neoplasia 17, 598–611 (2015)CrossRefPubMedPubMedCentral
89.
Zurück zum Zitat L.H. Moyes, H. McEwan, S. Radulescu, J. Pawlikowski, C.G. Lamm, C. Nixon, O.J. Sansom, J.J. Going, G.M. Fullarton, P.D. Adams, Activation of Wnt signalling promotes development of dysplasia in Barrett’s oesophagus. J Pathol 228, 99–112 (2012)PubMed L.H. Moyes, H. McEwan, S. Radulescu, J. Pawlikowski, C.G. Lamm, C. Nixon, O.J. Sansom, J.J. Going, G.M. Fullarton, P.D. Adams, Activation of Wnt signalling promotes development of dysplasia in Barrett’s oesophagus. J Pathol 228, 99–112 (2012)PubMed
90.
Zurück zum Zitat Y. Kitagawa, T. Uno, T. Oyama, K. Kato, H. Kato, H. Kawakubo, O. Kawamura, M. Kusano, H. Kuwano, H. Takeuchi, Y. Toh, Y. Doki, Y. Naomoto, K. Nemoto, E. Booka, H. Matsubara, T. Miyazaki, M. Muto, A. Yanagisawa, M. Yoshida, Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: Part 1. Esophagus. 16, 1–24 (2019)CrossRefPubMed Y. Kitagawa, T. Uno, T. Oyama, K. Kato, H. Kato, H. Kawakubo, O. Kawamura, M. Kusano, H. Kuwano, H. Takeuchi, Y. Toh, Y. Doki, Y. Naomoto, K. Nemoto, E. Booka, H. Matsubara, T. Miyazaki, M. Muto, A. Yanagisawa, M. Yoshida, Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: Part 1. Esophagus. 16, 1–24 (2019)CrossRefPubMed
91.
Zurück zum Zitat A.M. Dulak, P. Stojanov, S. Peng, M.S. Lawrence, C. Fox, C. Stewart, S. Bandla, Y. Imamura, S.E. Schumacher, E. Shefler, A. McKenna, S.L. Carter, K. Cibulskis, A. Sivachenko, G. Saksena, D. Voet, A.H. Ramos, D. Auclair, K. Thompson, C. Sougnez, R.C. Onofrio, C. Guiducci, R. Beroukhim, Z. Zhou, L. Lin, J. Lin, R. Reddy, A. Chang, R. Landrenau, A. Pennathur, S. Ogino, J.D. Luketich, T.R. Golub, S.B. Gabriel, E.S. Lander, D.G. Beer, T.E. Godfrey, G. Getz, A.J. Bass, Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 45, 478–486 (2013)CrossRefPubMedPubMedCentral A.M. Dulak, P. Stojanov, S. Peng, M.S. Lawrence, C. Fox, C. Stewart, S. Bandla, Y. Imamura, S.E. Schumacher, E. Shefler, A. McKenna, S.L. Carter, K. Cibulskis, A. Sivachenko, G. Saksena, D. Voet, A.H. Ramos, D. Auclair, K. Thompson, C. Sougnez, R.C. Onofrio, C. Guiducci, R. Beroukhim, Z. Zhou, L. Lin, J. Lin, R. Reddy, A. Chang, R. Landrenau, A. Pennathur, S. Ogino, J.D. Luketich, T.R. Golub, S.B. Gabriel, E.S. Lander, D.G. Beer, T.E. Godfrey, G. Getz, A.J. Bass, Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 45, 478–486 (2013)CrossRefPubMedPubMedCentral
92.
Zurück zum Zitat J.Y. Dai, X. Wang, M.F. Buas, C. Zhang, J. Ma, B. Wei, Y. Li, B. Zhao, T.S. Hyun, X. Chen, K.R. Loeb, R. Odze, L. Yao, X. Sun, S. Self, T.L. Vaughan, Y. Guo, Whole-genome sequencing of esophageal adenocarcinoma in Chinese patients reveals distinct mutational signatures and genomic alterations. Commun Biol 1, 174 (2018)CrossRefPubMedPubMedCentral J.Y. Dai, X. Wang, M.F. Buas, C. Zhang, J. Ma, B. Wei, Y. Li, B. Zhao, T.S. Hyun, X. Chen, K.R. Loeb, R. Odze, L. Yao, X. Sun, S. Self, T.L. Vaughan, Y. Guo, Whole-genome sequencing of esophageal adenocarcinoma in Chinese patients reveals distinct mutational signatures and genomic alterations. Commun Biol 1, 174 (2018)CrossRefPubMedPubMedCentral
Metadaten
Titel
Esophageal carcinoma: Towards targeted therapies
verfasst von
Ali Fatehi Hassanabad
Rania Chehade
Daniel Breadner
Jacques Raphael
Publikationsdatum
17.12.2019
Verlag
Springer Netherlands
Erschienen in
Cellular Oncology / Ausgabe 2/2020
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-019-00488-2

Weitere Artikel der Ausgabe 2/2020

Cellular Oncology 2/2020 Zur Ausgabe

Neu im Fachgebiet Pathologie